Phreesia (PHR) Insider Jon Kessler Buys $185K of Stock
Jon Kessler bought 19,290 shares of Phreesia, Inc. for approximately $185,000 on June 24, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Jon Kessler bought 19,290 shares of Phreesia, Inc. ($PHR) at an average price of $9.59, worth about $184,991.10, on June 24, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $PHR is up 11.8% after 1 week, up 6.6% after 1 month and up 14.1% to date (from the $9.59 close on Jun 24, 2026).
PHR
Phreesia, Inc.
Key Points
- Jon Kessler purchased 19,290 shares of Phreesia, Inc. for about $185,000 on June 24, 2026.
- Phreesia's stock recently traded at $9.13, down from a 52-week high of $25.00.
- Analysts maintain a consensus 'buy' rating for Phreesia with a target price averaging $13.94.
Get $PHR trade alerts by text
We text you when insiders, Congress or big funds trade $PHR. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Phreesia, Inc. alert may contain errors. Disclosures
Insider Buying and Selling at Phreesia, Inc.
On June 24, 2026, Jon Kessler bought 19,290 shares of Phreesia, Inc. (PHR) on the NYSE at a price of $9.59 per share, totaling about $185,000. This purchase reflects a commitment to the company as it continues to grow in the healthcare technology sector.
What Changed in Kessler's Position
Kessler's recent purchase adds 19,290 shares to his holdings in Phreesia, which enhances his stake in the company. This transaction is significant as it shows his confidence in Phreesia's future, especially considering the current market challenges.
Stock Performance and Market Context
Phreesia shares recently traded at $9.13, which is considerably lower than its 52-week high of $25.00. This decline may present an opportunity for investors like Kessler, who are looking to capitalize on potential recovery as the company navigates market conditions.
Analysts Set New Price Targets
On October 12, 2026, Barclays maintained its 'Equal-Weight' rating for Phreesia with a price target of $11.00, up from $10.00. However, Raymond James downgraded its rating to 'Market Perform' on September 8, 2026. Overall, analysts have a consensus 'buy' rating with a mean price target of $13.94, indicating a positive outlook for the company.
What PHR Does
Phreesia, Inc. provides a software and payment platform for the healthcare industry, helping organizations optimize patient intake and payment processes. Kessler's purchase underscores his belief in the company's potential growth and innovation in healthcare technology.
What's Ahead for PHR
Phreesia is set to report its next earnings on December 7, 2026. As Kessler and other insiders make significant purchases, it will be interesting to see how the market reacts and how the company's performance aligns with analyst expectations. Remember, Kessler's transaction reflects his position as of June 24, 2026, and may not represent his current holdings.
Related Filing Alerts
Source: Jon Kessler's Form 4 filing on $PHR (Jun 24, 2026). Find the original filing: PHR Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts